Obesity Surgery

, Volume 22, Issue 3, pp 472–477 | Cite as

Omental Gene Expression of Adiponectin Correlates with Degree of Insulin Sensitivity Before and After Gastric Bypass Surgery

Clinical Research

Abstract

Background

Circulating adiponectin is known to correlate negatively with insulin resistance in patients with obesity and diabetes. The aim of this study was to assess the effect of gastric bypass (GB) surgery on adiponectin gene expression in subcutaneous and omental adipose tissues.

Methods

Adipose tissues and plasma were obtained from 25 subjects undergoing GB surgery, 15 non-obese subjects, and 12 subjects after GB surgery. Real-time quantitative reverse transcription polymerase chain reaction was used for analysis of the adipose tissues. Adiponectin expression was normalized for glyceraldehyde 3-phosphate dehydrogenase and expressed as percentage of subject-matched subcutaneous expression which was given an arbitrary value of 100%. Insulin resistance was assessed by the homeostatic model assessment (HOMA). Circulating adiponectin was assayed by ELISA.

Results

Omental adiponectin gene expression was fivefold higher in subjects after GB when compared with age-matched morbidly obese subjects before GB (P < 0.01). There were no statistical differences in omental adiponectin gene expression observed in subjects after GB and age-matched non-obese subjects. For the entire cohort of subjects, there was a significant negative correlation between omental adiponectin expression and insulin resistance expressed by HOMA values (r = −0.62, P < 0.001). Circulating adiponectin was significantly lower (P < 0.05) in the obese group than in the non-obese and post-GB groups.

Conclusions

Omental adiponectin gene expression significantly increases after GB surgery reaching levels equal to age-matched non-obese subjects. Omental adiponectin expression has a significant negative correlation with the insulin resistance status.

Keywords

Adiponectin Gastric bypass surgery Bariatric surgery Omentum Adipose tissue Insulin resistance 

Notes

Acknowledgment

The study was supported by a National Institute of Health Grant: K23DK075907 (to AT).

Conflict of interest statement

All authors do not have any conflict of interest with an institution or product that is mentioned in the manuscript and/or is important to the outcome of the study presented.

References

  1. 1.
    Brancati FL, Whelton PK, Kuller LH, et al. Diabetes mellitus, race, and socioeconomic status. A population-based study. Ann Epidemiol. 1996;6:67–73.PubMedCrossRefGoogle Scholar
  2. 2.
    Folsom A, Rasmussen M, Chambless L, et al. Prospective associations of fasting insulin, body fat distribution, and diabetes with risk of ischemic stroke. The Atherosclerosis Risk in Communities (ARIC) Study Investigators. Diabetes Care. 1999;22:1077–83.PubMedCrossRefGoogle Scholar
  3. 3.
    Gabriely I, Ma XH, Yang XM, et al. Removal of visceral fat prevents insulin resistance and glucose intolerance of aging: an adipokine-mediated process? Diabetes. 2002;51:2951–8.PubMedCrossRefGoogle Scholar
  4. 4.
    Montague CT, O'Rahilly S. The perils of portliness: causes and consequences of visceral adiposity. Diabetes. 2000;49:883–8.PubMedCrossRefGoogle Scholar
  5. 5.
    Wajchenberg BL. Subcutaneous and visceral adipose tissue: their relation to the metabolic syndrome. Endo Rev. 2000;21:697–738.CrossRefGoogle Scholar
  6. 6.
    Lafontan M, Berlan M. Do regional differences in adipocyte biology provide new pathophysiological insights? Trends Pharmacol Sci. 2003;24:276–83.PubMedCrossRefGoogle Scholar
  7. 7.
    Bolinder J, Kager L, Ostman J, et al. Differences at the receptor and postreceptor levels between human omental and subcutaneous adipose tissue in the action of insulin on lipolysis. Diabetes. 1983;32:117–23.PubMedCrossRefGoogle Scholar
  8. 8.
    McCarty MF. Interleukin-6 as a central mediator of cardiovascular risk associated with chronic inflammation, smoking, diabetes, and visceral obesity: down-regulation with essential fatty acids, ethanol and pentoxifylline. Med Hypotheses. 1999;52:465–77.PubMedCrossRefGoogle Scholar
  9. 9.
    Itamar Raz RE, Cernea S, Shafrir E. Diabetes: insulin resistance and derangements in lipid metabolism. Cure through intervention in fat transport and storage. Diabetes/Metab Res Rev. 2005;21:3–14.CrossRefGoogle Scholar
  10. 10.
    Frayn KN. Obesity and metabolic disease: is adipose tissue the culprit? Proc Nutr Soc. 2005;64:7–13.PubMedCrossRefGoogle Scholar
  11. 11.
    Lau DC, Dhillon B, Yan H, et al. Adipokines: molecular links between obesity and atheroslcerosis. Am J Physiol Heart Circ Physiol. 2005;288:H2031–2041.PubMedCrossRefGoogle Scholar
  12. 12.
    Alessi MC, Bastelica D, Morange P, et al. Plasminogen activator inhibitor 1, transforming growth factor-beta1, and BMI are closely associated in human adipose tissue during morbid obesity. Diabetes. 2000;49:1374–80.PubMedCrossRefGoogle Scholar
  13. 13.
    Hotamisligil GS, Arner P, Caro JF, et al. Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. J Clin Invest. 1995;95:2409–15.PubMedCrossRefGoogle Scholar
  14. 14.
    Kern PA, Saghizadeh M, Ong JM, et al. The expression of tumor necrosis factor in human adipose tissue. Regulation by obesity, weight loss, and relationship to lipoprotein lipase. J Clin Invest. 1995;95:2111–9.PubMedCrossRefGoogle Scholar
  15. 15.
    Liu YM, Lacorte JM, Viguerie N, et al. Adiponectin gene expression in subcutaneous adipose tissue of obese women in response to short-term very low calorie diet and refeeding. J Clin Endocrinol Metab. 2003;88:5881–6.PubMedCrossRefGoogle Scholar
  16. 16.
    Garg A. Regional adiposity and insulin resistance. J Clin Endocrinol Metab. 2004;89:4206–10.PubMedCrossRefGoogle Scholar
  17. 17.
    Lin E, Phillips LS, Ziegler TR, et al. Increases in adiponectin predict improved liver, but not peripheral, insulin sensitivity in severely obese women during weight loss. Diabetes. 2007;56:735–42.PubMedCrossRefGoogle Scholar
  18. 18.
    Winer J, Jung CK, Shackel I, et al. Development and validation of real-time quantitative reverse transcriptase-polymerase chain reaction for monitoring gene expression in cardiac myocytes in vitro. Anal Biochem. 1999;270:41–9.PubMedCrossRefGoogle Scholar
  19. 19.
    Kadowaki T, Yamauchi T. Adiponectin and adiponectin receptors. Endocr Rev. 2005;26:439–51.PubMedCrossRefGoogle Scholar
  20. 20.
    Torquati A, Lutfi R, Abumrad N. Is Roux-en-Y gastric bypass surgery the most effective treatment for type 2 diabetes mellitus in morbidly obese patients? J Gastrointest Surg. 2005;9:1112–6. discussion 7–8.PubMedCrossRefGoogle Scholar
  21. 21.
    Torquati A, Wright K, Melvin W, et al. Effect of gastric bypass operation on Framingham and actual risk of cardiovascular events in class II to III obesity. J Am Coll Surg. 2007;204:776–82.PubMedCrossRefGoogle Scholar
  22. 22.
    Arita Y, Kihara S, Ouchi N, et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Comm. 1999;257:79–83.PubMedCrossRefGoogle Scholar
  23. 23.
    Hulver MW, Saleh O, MacDonald KG, et al. Ethnic differences in adiponectin levels. Metab Clin Exp. 2004;53:1–3.PubMedCrossRefGoogle Scholar
  24. 24.
    Manco M, Fernandez-Real JM, Equitani F, et al. Effect of massive weight loss on inflammatory adipocytokines and the innate immune system in morbidly obese women. J Clin Endocrinol Metab. 2007;92:483–90.PubMedCrossRefGoogle Scholar
  25. 25.
    Swarbrick MM, Austrheim-Smith IT, Stanhope KL, et al. Circulating concentrations of high-molecular-weight adiponectin are increased following Roux-en-Y gastric bypass surgery. Diabetologia. 2006;49:2552–8.PubMedCrossRefGoogle Scholar
  26. 26.
    Drolet R, Belanger C, Fortier M, et al. Fat depot-specific impact of visceral obesity on adipocyte adiponectin release in women. Obesity, Silver Spring, MD. 2009;17:424–30.CrossRefGoogle Scholar
  27. 27.
    Bruun JM, Lihn AS, Verdich C, et al. Regulation of adiponectin by adipose tissue-derived cytokines: in vivo and in vitro investigations in humans. Am J Physiol. 2003;285:E527–33.Google Scholar
  28. 28.
    Arvidsson E, Viguerie N, Andersson I, et al. Effects of different hypocaloric diets on protein secretion from adipose tissue of obese women. Diabetes. 2004;53:1966–71.PubMedCrossRefGoogle Scholar
  29. 29.
    Garaulet M, Viguerie N, Porubsky S, et al. Adiponectin gene expression and plasma values in obese women during very-low-calorie diet. Relationship with cardiovascular risk factors and insulin resistance. J Clin Endocrinol Metab. 2004;89:756–60.PubMedCrossRefGoogle Scholar
  30. 30.
    Viguerie N, Vidal H, Arner P, et al. Adipose tissue gene expression in obese subjects during low-fat and high-fat hypocaloric diets. Diabetologia. 2005;48:123–31.PubMedCrossRefGoogle Scholar
  31. 31.
    Coughlin CC, Finck BN, Eagon JC, et al. Effect of marked weight loss on adiponectin gene expression and plasma concentrations. Obesity, Silver Spring, MD. 2007;5:640–5.CrossRefGoogle Scholar
  32. 32.
    Altinova AE, Toruner F, Bukan N, et al. Decreased plasma adiponectin is associated with insulin resistance and HDL cholesterol in overweight subjects. Endocr J. 2007;54:221–6.PubMedCrossRefGoogle Scholar
  33. 33.
    Mojiminiyi OA, Abdella NA, Al Arouj M. Adiponectin, insulin resistance and clinical expression of the metabolic syndrome in patients with type 2 diabetes. Int J Obesity. 2007;31:213–20. 2005.CrossRefGoogle Scholar

Copyright information

© Springer Science + Business Media, LLC 2011

Authors and Affiliations

  1. 1.Department of SurgeryDuke UniversityDurhamUSA
  2. 2.Department of PediatricsUniversity of North CarolinaChapel HillUSA

Personalised recommendations